← Leaderboards
Diego E Rincon-Limas
University Of Florida
$5,926,703
Attributed
$5,926,703
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $793K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,926,703 · 9
By mechanism
R01$3,023,539 · 2
R21$2,903,164 · 7
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposDrosophila GenusPathologyNerve DegenerationToxic EffectProteinsS DiseaseNeuropathologyGenesMolecularPublic HealthGeneticPathogenesisPhenotypeMediatingPlayNeurotoxicHomologous GeneEffective TherapyPathologicTau ProteinsRna Interference ScreenPathway InteractionsComplex
Grant awards (21)
Can SARS-CoV-2 proteins accelerate Abeta pathology in fly and mouse models of AD?$419,375
R21 · FY2025 · AG · contact PI
Harnessing new targets and mechanisms mediating AD pathogenesis$373,625
R01 · FY2025 · AG · contact PI
Harnessing new targets and mechanisms mediating AD pathogenesis$381,250
R01 · FY2024 · AG · contact PI
Harnessing new targets and mechanisms mediating AD pathogenesis$368,373
R01 · FY2023 · AG · contact PI
Deconstructing and challenging TDP-43 proteinopathies: from FTLD/ALS to Alzheimer's disease$381,250
R01 · FY2022 · AG · contact PI
Deconstructing and challenging TDP-43 proteinopathies: from FTLD/ALS to Alzheimer's disease$381,250
R01 · FY2021 · AG · contact PI
Functional assessment of 1,500 human genes against coexistent Abeta and tau pathology in vivo$190,625
R21 · FY2021 · AG · contact PI
Deconstructing and challenging TDP-43 proteinopathies: from FTLD/ALS to Alzheimer's disease$381,250
R01 · FY2020 · AG · contact PI
Functional assessment of 1,500 human genes against coexistent Abeta and tau pathology in vivo$221,586
R21 · FY2020 · AG · contact PI
Deconstructing and challenging TDP-43 proteinopathies: from FTLD/ALS to Alzheimer's disease$381,250
R01 · FY2019 · AG · contact PI
Exploring the unparalleled protection of RAF2 against Abeta42 and tau toxicity$228,750
R21 · FY2019 · AG · contact PI
Deconstructing and challenging TDP-43 proteinopathies: from FTLD/ALS to Alzheimer's disease$375,291
R01 · FY2018 · AG · contact PI
Uncovering targets that block pathological interactions between Abeta and tau$190,625
R21 · FY2018 · AG · contact PI
Exploring the unparalleled protection of RAF2 against Abeta42 and tau toxicity$187,453
R21 · FY2018 · AG · contact PI
Uncovering targets that block pathological interactions between Abeta and tau$228,750
R21 · FY2017 · AG · contact PI
Targeting nuclear transport dysfunction in TDP-43 proteinopathies$187,500
R21 · FY2017 · NS · contact PI
Targeting nuclear transport dysfunction in TDP-43 proteinopathies$225,000
R21 · FY2016 · NS · contact PI
Optogenetic modeling of primary and secondary CNS proteinopathies in Drosophila$187,500
R21 · FY2015 · NS · contact PI
Optogenetic modeling of primary and secondary CNS proteinopathies in Drosophila$225,000
R21 · FY2014 · NS · contact PI
Engineering chaperones for extracellular amyloids$187,500
R21 · FY2014 · NS · contact PI
Engineering chaperones for extracellular amyloids$223,500
R21 · FY2013 · NS · contact PI